This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by Institute of Vision, Brasil.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Institute of Vision, Brasil Identifier:
First received: July 31, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted
The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Institute of Vision, Brasil:

Estimated Enrollment: 74
Study Start Date: January 2008

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eye clinic in Belo Horizonte, Brazil

Inclusion Criteria:

  • Diagnosis of neovascular age-related macular degeneration
  • Visual acuity better than 20/400
  • Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
  • Follow-up period of at least six months

Exclusion Criteria:

  • Choroidal neovascularization secondary to any other cause than age-related macular degeneration
  • Eyes with polypoidal choroidal vasculopathy
  • Eyes previously submitted to posterior vitrectomy
  • Other diseases that could affect visual acuity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01655589

Institute of Vision Recruiting
Belo Horizonte, MG, Brazil, 30150270
Contact: Andre B Ferreira    55 31 32743355   
Sponsors and Collaborators
Institute of Vision, Brasil
  More Information

Responsible Party: Institute of Vision, Brasil Identifier: NCT01655589     History of Changes
Other Study ID Numbers: IV-01
Study First Received: July 31, 2012
Last Updated: July 31, 2012

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on September 21, 2017